Technologies to assess CAR-T-cell serial killing in real-time got a big boost with the introduction of the xCELLigence RTCA eSight system. Advances in time-lapse microscopy and bioelectrical impedance have shed light on cytolytic activity in real time. However, the immediate close proximity of effector to target cells when CAR T cells are added to target cells can be a hindrance. As CAR Ts kill in a cooperative manner, they might only engage one-two targets in the entire assay. At lower effector:target ratios, the assay may reflect proliferative potential more than cytolytic potency.
This webcast will present an innovative advance and first-of-its kind assay, leveraging the xCELLigence RTCA eSIGHT technology to combine imaging with impedance analyses and separate effector CAR T cells from their antigen-positive targets utilizing a layer of matrigel.
As matrigel has tuneable density, its composition can be matched to reflect the physiochemical properties of distinct stromal regions across several tumor microenvironments. Uncoupling migration from cytolytic activity yields enhanced translational insights into the energy cost of CAR-T-cell killing and potential biomarkers of CAR-T-cell potency prior to clinical endpoints.
Learn:
• How CAR-T-cell migration can be measured independently from cytolytic activity during serial killing
• What separating migration from killing reveals about CAR-T-cell energy use and potency
• How tuneable matrigel models can better replicate tumor microenvironments to assess CAR-T function
Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by Agilent Technologies, Inc., who retains sole responsibility for content. About this content.
Speaker
Roddy O’Connor, Research Assistant Professor, Center for Cellular Immunotherapies, Perelman School of Medicine
Roddy O’Connor, PhD, pioneers metabolic engineering of CAR T cells, developing novel conditioning and genetic strategies to enhance resilience in hostile tumor environments. Recognized with the AAI Award for Excellence in Immunology, Dr O’Connor’s work bridges academia and industry to advance CAR T therapies for cancer and autoimmune disease.
Moderator
Nikki Forrester, Freelance Science Writer and Editor
Nikki Forrester is a science journalist who covers biology, natural history, climate, and the culture of academic research. She earned a Ph.D. in ecology and evolutionary biology in 2019.